| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
The Experienced MedTech Logistics Provider Will Help Ensure Effective and Efficient Inventory Management and Customer Support
The Company is on Track to Commence the Launch of LIBERTY® during Q4 This Year
HINGHAM, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributer of the innovative LIBERTY® Endovascular Robotic System, has partnered with a U.S. based third-party logistics (3PL) company to support the commercialization of the FDA-cleared LIBERTY® System. The Company is expected to initiate the limited market release of the LIBERTY® System during the current fourth quarter of 2025 with the broader launch anticipated to occur in April 2026 during the Society of Interventional Radiology conference, which is the largest Interventional Radiology conference in the U.S.
The 3PL company is a fully compliant and integrated fulfillment solutions provider specializing in the medical device industry, which would allow the Company to leverage its proximity to key markets, and provide effective and efficient order processing and the ability to maintain inventory to meet expected demand from a strategically located, climate-controlled warehouse.
Posted In: MBOT
